F018 Great Care for Common Conditions: Combining Evidence and Cost Effectiveness
DESCRIPTION
This session will examine the data and provide an evidenced based discussion about best cost effective practices to care for patients with acne, atopic dermatitis, HS, and urticaria.
LEARNING OBJECTIVES
Assess cost effective care of various skin diseases and conditions including photoaging, acne, hair and nail disease, among others.
Examine evidence that drives decision making for skin disease such as psoriasis and HS.
SCHEDULE
1:00 PM
Introduction
Scott Elman, MD, FAAD
1:05 PM
Hidradenitis Suppurativa
Alexandra P. Charrow, MD, FAAD
1:35 PM
Atopic Dermatitis
Jonathan I. Silverberg, MD, PhD, MPH, FAAD
2:05 PM
Acne
John S. Barbieri, MD, MBA, FAAD
2:35 PM
Urticaria
Scott Elman, MD, FAAD
DIRECTOR
Scott Elman, MD, FAAD
SPEAKERS
John S. Barbieri, MD, MBA, FAAD
Alexandra P. Charrow, MD, FAAD
Jonathan I. Silverberg, MD, PhD, MPH, FAAD
DISCLOSURES
John S. Barbieri, MD, MBA, FAAD
Alosa Health – Consultant (1099 relationship)(Fees); Galderma – Consultant (1099 relationship)(Fees); Honeydew Care – Consultant (1099 relationship)(Fees); National Institutes of Health – Other(Grants/Research Funding); National Psoriasis Foundation – Other(Grants/Research Funding); Sagimet Biosciences – Consultant (1099 relationship)(Fees); Sanofi – Consultant (1099 relationship)(Fees); TWi Biotechnology, Inc. – Consultant (1099 relationship)(Fees);
Alexandra P. Charrow, MD, FAAD
Avalo – Consultant (1099 relationship)(Fees); Dermatology Foundation – Investigator(Grants/Research Funding); Hidradenitis Suppurativa Foundation – Board of Directors(No Compensation Received), Investigator(Grants/Research Funding); Incyte Corporation – Advisory Board(Fees), Investigator(No Compensation Received); Insmed – Investigator(No Compensation Received); Insmed Incorporated – Investigator(No Compensation Received); Novartis Pharmaceuticals Corp. – Advisory Board(Fees); Q32 Bio Inc. – Consultant (1099 relationship)(No Compensation Received); Sonoma Biotherapeutics – Investigator(No Compensation Received); UCB Pharma – Advisory Board(Honoraria); Wedbush Securities – Consultant (1099 relationship)(Honoraria);
Scott Elman, MD, FAAD
Biogen – Consultant(Fees); Blueprint Medicines – Advisory Board(Fees); EMD Serono – Consultant (1099 relationship)(Fees); Pfizer Inc. – Investigator(Grants/Research Funding);
Jonathan I. Silverberg, MD, PhD, MPH, FAAD
AbbVie – Consultant(Honoraria), Speaker(Honoraria); Aldena Therapeutics – Advisory Board(Fees); Amgen – Consultant(Fees); Apollo Therapeutics Ltd – Consultant (1099 relationship)(Fees); Arcutis, Inc. – Consultant(Fees), Speaker(Fees); Attovia Therapeutics – Advisory Board(Fees); Castle Biosciences – Consultant(Fees); Connect Biopharma LLC – Consultant(Fees); Corevitas – Advisory Board(Honoraria); Eli Lilly and Company – Consultant(Honoraria), Speaker(Fees); Enveda Biosciences – Consultant (1099 relationship)(Fees); Galderma – Speaker(Fees); Galderma Research & Development, LLC – Consultant(Honoraria); GlaxoSmithKline – Consultant(Honoraria), Investigator(No Compensation Received); Imagene Bio – Consultant (1099 relationship)(Fees); Imagene Biopharmaceuticals – Consultant (1099 relationship)(Fees); Incyte Corporation – Consultant(Honoraria); Infimmune – Advisory Board(Fees); Leo Pharma Inc – Advisory Board(Honoraria); Leo Pharma Inc. – Investigator(Honoraria); Maui Derm – Speaker(Fees); Nektar Therapeutics – Consultant (1099 relationship)(Fees); Novartis – Consultant(Fees); Organon – Speaker(Fees); Pfizer Inc. – Advisory Board(Honoraria), Consultant(Honoraria), Speaker(Fees); Regeneron – Consultant(Honoraria), Investigator(No Compensation Received), Speaker(Honoraria); Sanofi – Consultant(Grants/Research Funding); Sanofi Genzyme – Speaker(Honoraria); Shaperon – Consultant(Fees); UCB – Consultant (1099 relationship)(Fees); UpToDate – Other(Fees);